Katalyst Continues Worldwide Growth by Acquiring Geopost Energy
14.9.2022 16:03:00 EEST | Business Wire | Press release
Katalyst Data Management announced today that it will acquire the Rio de Janeiro-based oil and gas data product and service provider Geopost Energy. Geopost Energy provides instant online access to integrated data of all types, including seismic, interpretations, and well logs production data to its clients. In addition, Geopost offers continuously updated information and news on all aspects of Brazil’s offshore and onshore E&P activities. The acquisition represents an important expansion to the South American region for Katalyst, underpinning their increasing capabilities to support their customers in any region they operate. The Brazilian office will act as a hub for Katalyst in South America and add to Katalyst’s global footprint including data centers in Canada, the United States, the United Kingdom, Australia, and Malaysia.
The transaction is subject to customary closing conditions.
Global reach for end-to-end subsurface data management
“This acquisition marks another milestone in our journey to have a presence in major oil and gas data markets across the globe,” said Katalyst President and CEO, Steve Darnell. “We have long admired the technology and services that Geopost brings to the market. In addition to the growth of Geopost’s products into our existing regions, we are excited about our ability to incorporate their key technologies into iGlass and SeismicZone. We believe this will greatly enhance our already industry leading capabilities.”
“We are thrilled to become part of the Katalyst family," said Christiano Lopes, Geopost’s CEO. “The combination of Katalyst’s industry leading organization, global footprint, and expertise with the technology and services developed by Geopost will contribute to a broader solution generating new opportunities in multiple regions. It is a huge opportunity for us as we advance.”
About Katalyst
Katalyst Data Management provides a complete data management solution assisting oil and gas companies with the difficult challenge of managing the vast amount of subsurface data and information acquired for exploration and production. Katalyst’s end-to-end solution includes every step in the process, from data capture and verification, data storage and organization, to marketing seismic data online. Katalyst’s signature offerings include the web-based iGlass solution for subsurface data management and the ecommerce site SeismicZone for data marketing. To learn more about Katalyst, visit www.katalystdm.com.
About Geopost Energy
With their leading technology platform, Geopost provides instant access to data related to the E&P market (e.g., seismic data, interpretations, wells, production charts, bidding round history, E&P assets, and others). Everything is built into a fluid and easy-to-use platform. The environment combines customer’s private library with automatically updated information covering all aspects of Brazil's E&P Offshore and Onshore activities. Geopost is an essential tool for your technical and business team.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005050/en/
Contact information
Katalyst Data Management
Steve Darnell, President and CEO
Steve.Darnell@katalystdm.com
+1 281.529.3202
Geopost Energy
Christiano Lopes, CEO
Christiano.Lopes@geopostenergy.com
+55 21 3535 9698
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom